Table 3.
The baseline characteristics of the patients treated with IC plus CCRT or CCRT alone in each risk group based on the propensity score matching method.
| Characteristic | High-risk group |
Intermediate-risk group |
Low-risk group |
||||||
|---|---|---|---|---|---|---|---|---|---|
| CCRT alone (n = 102) |
IC + CCRT (n = 304) |
p value | CCRT alone (n = 449) |
IC + CCRT (n = 867) |
p value | CCRT alone (n = 203) |
IC + CCRT (n = 230) |
p value | |
| No. (%)a | No. (%)a | No. (%)a | No. (%)a | No. (%)a | No. (%)a | ||||
| Sex | 0.599 | 0.657 | 0.275 | ||||||
| Male | 14 (13.7) | 35 (11.5) | 88 (19.6) | 161 (18.6) | 81 (39.9) | 80 (34.8) | |||
| Female | 88 (86.3) | 269 (88.5) | 361 (80.4) | 706 (81.4) | 122 (60.1) | 150 (65.2) | |||
| T-stage (8th edition) | 0.571 | 0.093 | 0.266 | ||||||
| T1 | 1 (1.0) | 2 (0.7) | 48 (10.7) | 64 (7.4) | 53 (26.1) | 52 (22.6) | |||
| T2 | 5 (4.9) | 10 (3.3) | 75 (16.7) | 146 (16.8) | 57 (28.1) | 52 (22.6) | |||
| T3 | 72 (70.6) | 206 (67.8) | 246 (54.8) | 466 (53.7) | 92 (45.3) | 123 (53.5) | |||
| T4 | 24 (23.5) | 86 (28.3) | 80 (17.8) | 191 (22.0) | 1 (0.5) | 3 (1.3) | |||
| N-stage (8th edition) | 0.316 | 0.612 | 0.862 | ||||||
| N2 | 34 (33.3) | 85 (28.0) | 319 (71.0) | 604 (69.7) | 187 (92.1) | 210 (91.3) | |||
| N3 | 68 (66.7) | 219 (72.0) | 130 (29.0) | 263 (30.3) | 16 (7.9) | 20 (8.7) | |||
| EBV DNA, copy/mlb | 0.758 | 0.939 | 0.956 | ||||||
| <1000 | 0 (0) | 0 (0) | 60 (13.4) | 117 (13.5) | 170 (83.7) | 195 (84.8) | |||
| 1000–9999 | 6 (5.9) | 16 (5.3) | 190 (42.3) | 352 (40.6) | 25 (12.3) | 26 (11.3) | |||
| 10,000–99,999 | 46 (45.1) | 150 (49.3) | 169 (37.6) | 340 (39.2) | 8 (3.9) | 9 (3.9) | |||
| ⩾100,000 | 50 (49.0) | 138 (45.4) | 30 (6.7) | 58 (6.7) | 0 (0) | 0 (0) | |||
| HGB, g/lb | 0.249 | 0.597 | 0.051 | ||||||
| <113 | 5 (4.9) | 7 (2.3) | 6 (1.3) | 7 (0.7) | 0 (0) | 0 (0) | |||
| 113–151 | 73 (71.6) | 209 (68.8) | 298 (66.4) | 585 (67.5) | 147 (72.4) | 146 (63.5) | |||
| ⩾151 | 24 (23.5) | 88 (28.9) | 145 (32.3) | 276 (31.8) | 56 (27.6) | 84 (36.5) | |||
| hs-CRP, g/mlb | 0.906 | 0.722 | 0.661 | ||||||
| <1.0 | 14 (13.7) | 42 (13.8) | 118 (26.3) | 217 (25.0) | 87 (42.9) | 93 (40.4) | |||
| 1.0–3.0 | 25 (24.5) | 81 (26.6) | 163 (36.3) | 334 (38.5) | 93 (45.8) | 115 (50.0) | |||
| ⩾3.0 | 63 (61.8) | 181 (59.5) | 168 (37.4) | 316 (36.4) | 23 (11.3) | 22 (9.6) | |||
| LDH, U/lb | 0.085 | 0.487 | 0.999 | ||||||
| <245 | 63 (61.8) | 216 (71.1) | 440 (98.0) | 855 (98.6) | 203 (100) | 230 (100) | |||
| ⩾245 | 39 (38.2) | 88 (28.9) | 9 (2.0) | 12 (1.4) | 0 (0) | 0 (0) | |||
CCRT, concurrent chemoradiotherapy; EBV, Epstein–Barr virus; HGB, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; IC, induction chemotherapy; LDH, lactate dehydrogenase; NPC, nasopharyngeal carcinoma.
a
Percentages may not add up to 100, due to rounding.
b
All variables were measured before treatment.